News
BGNE
144.12
+3.69%
5.13
EU regulators approve BeiGene's tislelizumab for lung cancer
EU regulators approve BeiGene's tislelizumab for lung cancer. The drug was approved for the treatment of three types of non-small cell lung cancer, or NSCLC. BeiGene plans to combine the lung cancer indications with an approved indication for esophageal cancer.
Seeking Alpha · 1d ago
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Shares of HealthStream, Inc. Rose sharply on Tuesday following upbeat quarterly results. The Nasdaq Composite gained over 200 points in Tuesday's session. Hibbett shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion.
Benzinga · 1d ago
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
European Commission has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) for first- and second-line use. BeiGene plans to combine the two indications under the brand name TEVIMBRA in the EU later in 2024.
Barchart · 2d ago
Weekly Report: what happened at BGNE last week (0415-0419)?
Weekly Report · 2d ago
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
BeiGene, Ltd. (NASDAQ:BGNE) has US$886.0m of debt, but it also has a healthy balance sheet. The company uses debt to fund its business, but is this a concern for shareholders? Debt is an important factor to consider when looking at a company's risk. BeiGene had a loss of US$1.8b over the last year, but has net cash of $2.29b. It has no debt and is in a position to turn a profit in the future.
Simply Wall St · 3d ago
Weekly Report: what happened at BGNE last week (0408-0412)?
Weekly Report · 04/15 09:05
BeiGene Is Maintained at Neutral by B of A Securities
Dow Jones · 04/08 16:45
BeiGene Price Target Cut to $164.30/Share From $179.30 by B of A Securities
Dow Jones · 04/08 16:45
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $164.3
Benzinga · 04/08 16:34
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Alcon (ALC) and Teladoc (TDOC)
TipRanks · 04/08 10:04
Weekly Report: what happened at BGNE last week (0401-0405)?
Weekly Report · 04/08 09:05
China's Hillhouse logs hefty decline in hedge fund assets in 2023
China's Hillhouse Investment saw its hedge fund assets plummet by a third last year to $27.5 billion. Hillhouse is known for long-term bets on Chinese tech, consumer goods and healthcare companies. Several U.S.-based investors have withdrawn their capital from the firm. The hedge fund's assets are expected to decline by a similar amount in 2023.
Reuters · 04/08 07:31
Weekly Report: what happened at BGNE last week (0325-0329)?
Weekly Report · 04/01 09:05
BeiGene, Ltd. (NASDAQ:BGNE) is largely controlled by institutional shareholders who own 41% of the company
A total of 5 investors have a majority stake in BeiGene, Ltd. (NASDAQ:BGNE) with 41% of the company. The company is owned by institutions with a majority of the stock. The top 5 shareholders of BeiGene have a total of 52% ownership of the business. We look at the company's ownership of shares. BeiGene has a large number of shares in the company and could be vulnerable to insider selling. It's worth looking at the insider ownership of a company to see how the company is run.
Simply Wall St · 03/31 14:52
4 Analysts Assess BeiGene: What You Need To Know
BeiGene Ltd is a commercial-stage biotechnology company developing drugs for the treatment of cancer. 4 analysts have published ratings on BeiGene in the last three months. The company has an average 12-month price target of $219.25. BeiGene has a positive revenue growth rate of 66.91% over the past year.
Benzinga · 03/27 15:00
BeiGene Is Maintained at Market Perform by Bernstein
Dow Jones · 03/27 08:59
BeiGene Price Target Cut to $161.00/Share From $196.00 by Bernstein
Dow Jones · 03/27 08:59
Bernstein Maintains Market Perform on BeiGene, Lowers Price Target to $161
Benzinga · 03/27 08:48
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
TipRanks · 03/26 23:50
Beigene Ltd: Report of proposed sale of securities
Press release · 03/26 21:16
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.